Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)

Informazioni relative al progetto

TUDCA-ALS

ID dell’accordo di sovvenzione: 755094

DOI

10.3030/755094

Progetto chiuso

Data della firma CE 15 Novembre 2017

Data di avvio 1 Gennaio 2018

Data di completamento 31 Dicembre 2023

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 5 596 928,00

Contributo UE

€ 5 596 928,00

Coordinato da

HUMANITAS MIRASOLE SPA
Italy

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Open Research Data Pilot (1)

Report on status of posting results in the study registry

Report on status of posting results in the study registry. The report will include the status of the result posting as well as the timelines when final posting of results is scheduled at end of funding period (Month 72)

Documents, reports (4)

Dissemination and exploitation plan

Dissemination and Exploitation Plan. The document will describe the dissemination and exploitation strategies and action plan (Month 3

Statistical analysis of primary and secondary outcome variables

Statistical analysis of primary and secondary outcome variables. (Month 72) This report will include the statistical analysis on primary and secondaty outcome variables

Demographic and clinical description of the study population

This report will include study population data on demographic and clinical aspects

Statistical analysis of biomarker and correlation with clinical outcomes

Statistical analysis of biomarker and correlation with clinical outcomes. (Month 66) This report will include data on statistical analysis of biomarkers and related correlation to clinical outcomes.

Websites, patent fillings, videos etc. (1)

Project website

Project website. The report will include the characteristics of the website, the activities involved for its creation and print screens of the website pages (Month 6

Pubblicazioni

Peer reviewed articles (6)

Review of disease-modifying drug trials in amyotrophic lateral sclerosis

Autori: Paolo Tornese; Stefania Lalli; Antoniangela Cocco; Alberto Albanese
Pubblicato in: Journal of Neurology Neurosurgery and Psychiatry, Numero 3, 2022, Pagina/e 521-529, ISSN 0022-3050
Editore: BMJ Publishing Group
DOI: 10.1136/jnnp-2021-328470

Tauro-Urso-Deoxycholic Acid Trials in Amyotrophic Lateral Sclerosis: What is Achieved and What to Expect

Autori: Maria Lo Giudice, Antoniangela Cocco, Giorgio Reggiardo, Stefania Lalli, Alberto Albanese
Pubblicato in: Clinical Drug Investigation, 2023, ISSN 1179-1918
Editore: Springer
DOI: 10.1007/s40261-023-01324-0

Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases

Autori: Kareem Khalaf; Paolo Tornese; Antoniangela Cocco; Alberto Albanese
Pubblicato in: Translational Neurodegeneration, Numero 3, 2022, Pagina/e 33, ISSN 2047-9158
Editore: Springer Nature
DOI: 10.1186/s40035-022-00307-z

A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial

Autori: Flavia L Lombardo, Stefania Spila Alegiani, Flavia Mayer, Marta Cipriani, Maria Lo Giudice, Albert Christian Ludolph, Christopher J McDermott, Philippe Corcia, Philip Van Damme, Leonard H Van den Berg, Orla Hardiman, Gabriele Nicolini, Nicola Vanacore, Brian Dickie, Alberto Albanese, Maria Puopolo; TUDCA-ALS Study Group (Paolo Tornese, Antoniangela Cocco, Michela Matteoli, Eliana Lauranzano, Maria
Pubblicato in: Trials, 2023, ISSN 1745-6215
Editore: BioMed Central
DOI: 10.1186/s13063-023-07638-w

Cox regression and survival analysis from the tauro-urso-deoxycholic trial in amyotrophic lateral sclerosis

Autori: Giorgio Reggiardo; Maria Lo Giudice; Stefania Lalli; Gilberto Rinaldi; Alberto Albanese
Pubblicato in: Frontiers in Neurology, Numero 5, 2023, ISSN 1664-2295
Editore: Frontiers Research Foundation
DOI: 10.3389/fneur.2023.1163855

Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol

Autori: Alberto Albanese, Albert Christian Ludolph, Christopher J McDermott, Philippe Corcia, Philip Van Damme, Leonard H Van den Berg, Orla Hardiman, Gilberto Rinaldi, Nicola Vanacore, Brian Dickie, TUDCA-ALS Study Group (Tornese Paolo, Cocco Antoniangela, Lo Giudice Maria, Matteoli Michela, Lauranzano Eliana, Malosio Maria Luisa, Adriana Elia Chiara, Lombardo Flavia, Mayer Flavia, Puopolo Maria, Alegian
Pubblicato in: Frontiers in Neurology, Numero 16642295, 2022, ISSN 1664-2295
Editore: Frontiers Research Foundation
DOI: 10.3389/fneur.2022.1009113